Physician profile
Thomas T Vovan
NPI 1134226012
$9,616.99
in general payments reported to CMS, 2019-2025
43 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $578 · 2021: $839 · 2022: $2,318 · 2023: $1,998 · 2024: $1,594 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,905 · Education: $72.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,904.55 |
| Education | $72.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,861.40 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Intuitive Surgical, INC. | $1,602.96 | 2022-2025 | Da Vinci Surgical System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,585.85 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $761.94 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Inari Medical, INC. | $422.53 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Noah Medical Corporation | $313.05 | 2024 | Galaxy |
| Insmed, INC. | $239.41 | 2021-2025 | Arikayce |
| Grifols USA, LLC | $234.40 | 2019-2025 | Prolastin-C Liquid |
| Pulmonx Corporation | $201.69 | 2021-2024 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Baxter Healthcare | $170.58 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Abbvie INC. | $166.54 | 2023-2025 | Alloderm |
| Gilead Sciences, INC. | $147.14 | 2023-2024 | Vemlidy |
| Lilly USA, LLC | $139.52 | 2025 | Zepbound |
| Regeneron Healthcare Solutions, INC. | $135.54 | 2021-2024 | Dupixent |
| Veran Medical Technologies, INC. | $132.23 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Vovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.